Bruker Announces European Launch of Toxtyper™, a Novel Clinical Mass Spectrometry Screening Solution for Toxicology
September 26 2012 - 3:00AM
Business Wire
At the annual conference of the DGKL (Deutsche Vereinte
Gesellschaft für Klinische Chemie und Laboratoriumsmedizin –see
www.dgkl.de), Bruker today announced the European launch of the
novel, automated Toxtyper™ clinical mass spectrometry
solution to meet the increasing demands for LC-MS/MS throughput and
data quality in routine toxicology laboratories without the need
for mass spectrometry expertise. The Toxtyper solution
provides faster and more reliable identification of toxins and
drugs of abuse within 10 minutes at therapeutic and toxic levels.
Bruker developed the Toxtyper solution with a library of 850
compounds in close collaboration with Jürgen Kempf at the Institute
of Forensic Medicine in Freiburg, Germany, and with Professor Denis
Hochstrasser and Dr. Marc Fathi’s team at the Geneva University
Hospital (HUG - Hôpitaux Universitaires de Genève) in
Switzerland.
Toxtyper (Photo: Business Wire)
The Toxtyper solution sets a new standard in LC-MS/MS
identification without requiring method development or mass
spectrometry expertise. Results and libraries are easily
transferable from lab to lab due to Bruker’s patented
SmartFrag™ technology, an innovation that essentially
removes variation and tuning from the MS/MS process.
SmartFrag uniquely positions Toxtyper as a
best-in-class, robust solution for rapid adoption in routine and
acute clinical toxicology.
Transferability and reproducibility of the novel Toxtyper
solution were validated by an inter-laboratory ring test using 4
spiked test serum samples measured by 7 Toxtyper systems in
5 different laboratories. A positive, correct identification rate
of well over 90% was reported by all participants, confirming the
easy adoption, high performance and transferability of the
Toxtyper method.
The Toxtyper solution combines novel library
identification algorithms and a high quality library of
toxicological compounds with Bruker’s high-performance amaZon
speed ion trap mass spectrometer coupled to an UHPLC system.
This efficient and robust system provides ultrafast identification
of drugs and toxins, with better throughput, compound coverage,
selectivity and more reliable identification than previous LC-only
or LC-MS/MS based toxicology systems. Key technologies to achieve
such robust and reliable toxicology identification performance
include the use of continuous, zero-delay positive/negative ion
switching, high MS/MS specificity and -importantly - novel,
on-the-fly MS3 product ion confirmation.
Jürgen Kempf of the Institute of Forensic Medicine in Freiburg,
Germany commented: “The combination of a simple push-button
solution with the performance of the trap technology makes the
Toxtyper solution a valuable tool for routine and research
forensics labs.”
Dr. Marc Fathi from the Geneva University Hospital (HUG -
Hôpitaux Universitaires de Genève) commented: “We are using two
Toxtyper systems for the routine toxicological screening of
patients admitted to the emergency room and profit from the
ease-of-use and fast result generation of this solution.”
In parallel, the routine applicability of the Toxtyper
solution is evaluated together with PD Dr. Peter Findeisen at the
Institute for Clinical Chemistry, Mannheim (UMM), who commented:
“We are using the system for routine screening of patients that are
admitted to the emergency room of the UMM with suspected
intoxications. The specificity of the method and shortened
turnaround times are rather impressive, and perfectly fit the
demands for general unknown screening.”
The new Toxtyper solution builds on the success of the
MALDI Biotyper, the very successful Bruker mass spectrometry
solution which has transformed clinical microbiology identification
in recent years with faster time-to-result (TTR), lower consumables
cost and more differentiated species and strain information on over
4,000 strains in a high-quality IVD-CE microbial identification
database.
The amaZon speed series of ion trap mass spectrometers
delivers small molecule sensitivity in the femtogram region,
Zero-Delay Alternating (ZDA™) polarity switching and
outstanding scanning speed at 52,000 u/sec. This performance allows
one-shot, 10 minute analysis of basic and acidic compounds in a
single UHPLC separation, delivering reliable Toxtyper
identification with the fastest identification rate in the
market.
The amaZon speed is a proven robust platform, ideal for
multi-user environments, and supported by Bruker’s unique
Compass OpenAccess software, a web-based client-server
system that enables a push-button solution for automatic library
searches. The performance of the amaZon speed delivers
excellent data quality for a range of additional clinical small
molecule applications, such as quantitative therapeutic drug
monitoring (TDM) by sensitive and fast LC-MS/MS methods in less
than 5 minutes. Novel software for automated assignment of
structures to fragment ions offers metabolite identification and
structure verification by MSn.
The Toxtyper initially is a ‘For Research Use Only’
solution available in Europe. For more information on amaZon
speed, please visit www.bdal.com
About Bruker Corporation
Bruker Corporation (NASDAQ: BRKR) is a leading provider of
high-performance scientific instruments and solutions for molecular
and materials research, as well as for industrial and applied
analysis. For more information about Bruker Corporation, please
visit www.bruker.com.
Photos/Multimedia Gallery Available:
http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50418915&lang=en
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jul 2023 to Jul 2024